Loadingβ¦
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (ΒCRISPRΒ)/CRISPR associated 9 (ΒCas9Β) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $68M | $-425M | $-413M | $-396M | -61.5% | 16.9% | - |
| 2024 | $58M | $-524M | $-519M | $-355M | -59.5% | 59.6% | - |
| 2023 | $36M | $-506M | $-481M | $-408M | -45.8% | -30.4% | - |
| 2022 | $52M | $-451M | $-474M | $-392M | -38.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 52.12 | 36.27 | 57.88 | 67.67 |
| Operating Expense | 510.29 | 551.57 | 592.14 | 508.66 |
| Operating Income | -458.16 | -515.29 | -534.26 | -440.99 |
| EBITDA | -450.59 | -506.31 | -523.98 | -425.07 |
| EBIT | -458.16 | -515.29 | -534.26 | -440.99 |
| Pretax Income | -474.19 | -481.19 | -519.02 | -412.69 |
| Net Income | -474.19 | -481.19 | -519.02 | -412.69 |
| Net Income Common Stockholders | -474.19 | -481.19 | -519.02 | -412.69 |
| Total Expenses | 510.29 | 551.57 | 592.14 | 508.66 |
| Interest Income | 8.54 | 49.83 | 47.81 | 29.20 |
| Research And Development | 419.98 | 435.07 | 466.31 | 388.86 |
| Selling General And Administration | 90.31 | 116.50 | 125.83 | 119.80 |
| Normalized EBITDA | -437.11 | -506.21 | -491.41 | -424.17 |
| Normalized Income | -460.70 | -481.09 | -486.46 | -411.80 |
| Basic EPS | -6.16 | -5.42 | -5.25 | -3.81 |
| Diluted EPS | -6.16 | -5.42 | -5.25 | -3.81 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | -13.48 | -0.10 | -32.56 | -0.90 |
| Total Unusual Items Excluding Goodwill | -13.48 | -0.10 | -32.56 | -0.90 |
| Net Income From Continuing Operation Net Minority Interest | -474.19 | -481.19 | -519.02 | -412.69 |
| Reconciled Depreciation | 7.57 | 8.98 | 10.29 | 15.92 |
| Net Interest Income | 8.54 | 49.83 | 47.81 | 29.20 |
| Net Income From Continuing And Discontinued Operation | -474.19 | -481.19 | -519.02 | -412.69 |
| Total Operating Income As Reported | -458.16 | -515.29 | -534.26 | -440.99 |
| Diluted Average Shares | 76.97 | 88.77 | 98.85 | 108.38 |
| Basic Average Shares | 76.97 | 88.77 | 98.85 | 108.38 |
| Diluted NI Availto Com Stockholders | -474.19 | -481.19 | -519.02 | -412.69 |
| Net Income Including Noncontrolling Interests | -474.19 | -481.19 | -519.02 | -412.69 |
| Net Income Continuous Operations | -474.19 | -481.19 | -519.02 | -412.69 |
| Other Income Expense | -24.56 | -15.73 | -32.56 | -0.90 |
| Special Income Charges | -13.48 | -0.10 | 0 | 0 |
| Restructuring And Mergern Acquisition | 13.48 | 0.10 | 0 | 0 |
| Earnings From Equity Interest | -11.08 | -15.63 | 0 | 0 |
| Gain On Sale Of Security | 0 | 0 | -32.56 | -0.90 |
| Net Non Operating Interest Income Expense | 8.54 | 49.83 | 47.81 | 29.20 |
| Interest Income Non Operating | 8.54 | 49.83 | 47.81 | 29.20 |
| General And Administrative Expense | 90.31 | 116.50 | 125.83 | 119.80 |
| Other Gand A | 90.31 | 116.50 | 125.83 | 119.80 |
| Operating Revenue | 52.12 | 36.27 | 57.88 | 67.67 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Intellia Therapeutics, Inc.this co. | NTLA | $1.5B | - | 2.16 | -61.5% | -2.58 |
| UFP Technologies, Inc. | UFPT | $1.5B | 22.59 | 3.64 | 16.1% | 15.05 |
| Nuvation Bio Inc. | NUVB | $1.5B | - | 4.92 | -66.9% | -4.95 |
| Harrow, Inc. | HROW | $1.5B | - | 28.56 | -9.9% | 34.30 |
| Iovance Biotherapeutics, Inc. | IOVA | $1.5B |
| - |
| 1.95 |
| -56.0% |
| -3.08 |
| Ardelyx, Inc. | ARDX | $1.5B | - | 8.80 | -36.9% | -38.06 |
| Precigen, Inc. | PGEN | $1.5B | - | 69.83 | -1198.6% | -14.11 |
| Aveanna Healthcare Holdings Inc. | AVAH | $1.4B | 6.24 | 7.08 | 115.3% | 9.48 |
| Maze Therapeutics, Inc. | MAZE | $1.4B | - | 3.57 | -36.9% | -6.82 |
| Peer Median | - | 14.41 | 6.00 | -36.9% | -4.02 | |